Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience

Mollengarden, Daniel; Goldberg, Kenneth; Wong, Daniel; Roehrborn, Claus G.

doi:10.1038/s41391-017-0022-9

Cited by 66 publications

(77 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urolift: a single-center retrospective study [10], a multicenter blinded randomized controlled trial (RCT) with 5 year follow-up [11][12][13], a multicenter non-blinded RCT with 2 year follow-up [14,15], a retrospective study with prospectively collected data [16], and a multicenter non-randomized prospective study [17]. Rezūm: a multicenter blinded RCT with 4 year follow-up [18], a cross-over study from the RCT [19], a multicenter retrospective study [20], a single-center retrospective study [21], and a prospective nonrandomized pilot study [22]. Ultimately, a total of 81, 418, and 505 patients were recruited for iTIND, Urolift and Rezūm, respectively.…”

Section: Resultsmentioning

confidence: 99%

Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm

et al. 2020

View full text Add to dashboard Cite

Purpose To review and discuss the literature regarding iTIND, Urolift and Rezūm and investigate the precise clinical indications of all three different approaches for their application in benign prostatic hyperplasia (BPH) treatment. Materials and methods The PubMed–Medline and Cochrane Library databases were screened to identify recent English literature relevant to iTIND, Urolift and Rezūm therapies. The surgical technique and clinical results for each approach were summarized narratively. Results iTIND, Urolift and Rezūm are safe and effective minimally invasive procedures for the symptomatic relief of lower urinary tract symptoms (LUTS) due to BPH. iTIND requires the results of ongoing prospective studies, a long-term follow-up and a comparison against a reference technique to confirm the generalizability of the first pivotal study. Urolift provides symptomatic relief but the improvements are inferior to TURP at 24 months and long-term retreatments have not been evaluated. Rezūm requires randomized controlled trials against a reference technique to confirm the first promising clinical results. However, clinical evidence from prospective clinical trials demonstrates the efficacy and safety of these procedures in patients with small- and medium-sized prostates. Conclusions Although iTIND, Urolift, and Rezūm cannot be applied to all bladder outlet obstruction (BOO) cases resulting from BPH, they provide a safe alternative for carefully selected patients who desire symptom relief and preservation of erectile and ejaculatory function without the potential morbidity of more invasive procedures.

show abstract

Section: Resultsmentioning

confidence: 99%

Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several other studies have reported similar improvements in LUTS due to BPH without a negative impact on sexual function at 1-2 years. 12,13 Early results from the UK were reported at the British Association of Urological Surgeons meeting in 2018 and are due to be presented at the European Association of Urology meeting in 2019. Rezum treatments in the UK have also received positive feedback from patients (see Box 1).…”

Section: Resultsmentioning

confidence: 99%

Rezum water vapour therapy for benign prostatic hyperplasia

Johnston

Hindley

2019

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

“…Significantly, sexual function is well preserved after this procedure, with ejactulatory dysfucntion occuring in only 3% of subjects; erectile function impairment was noted only among patients with a previous dysfunction 18, 21 . Among main complications, urinary tract infection occurred in 17% of patients and a transient urinary retention after catheter withdrawn happened in 14% of cases, while other complications such as urethral stenosis occurred in less than 4% of patients 18 . Efficacy of the procedure was not related to prostate volume.…”

Section: Tissue Ablationmentioning

confidence: 98%

“…Patients are discharged on the same day of the procedure and should keep an indwelling bladder catheter for 1 week. Available studies to date have demonstrated that, after procedure, there is an increase in urinary flow rate of up to 6 milliliters per second, as well as a 11-point improvement of symptoms as evaluated with the IPSS 18,19 . So far, efficacy of the results has been demonstrated at the end of a 2-year follow-up 19 .…”

Section: Tissue Ablationmentioning

confidence: 99%

“…So far, efficacy of the results has been demonstrated at the end of a 2-year follow-up 19 . Furthermore, prostate volume in patients undergoing Rezum ablation has decrease by 17 to 28% 18,20 . Significantly, sexual function is well preserved after this procedure, with ejactulatory dysfucntion occuring in only 3% of subjects; erectile function impairment was noted only among patients with a previous dysfunction 18, 21 .…”

Section: Tissue Ablationmentioning

confidence: 99%

See 1 more Smart Citation

Minimally invasive techniques for the treatment of benign prostatic hyperplasia

Barbosa

Antunes

2018

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Benign Prostatic Hyperplasia (BPH) occurs in up to 80% of men older than 70 years. The prevalence of BPH increases with age, from approximately 25% of men at 50 years of age to 50 to 90% of individuals in their 8th decade of life. Treatment options for lower urinary tract symptoms (LUTS) secondary to BPH have been long restricted to drug therapy and, after failure of the former, surgical treatment. However, prostate surgery is associated with risks such as bleeding, necessity of transfusion and ejaculatory dysfunction. Several novel and minimally invasive methods for treatment of BPH have arisen in the past years. Common to all of these techniques are a more favorable safety profile and varying rates of success and clinical improvement, however frequently inferior to standard surgical techniques. Patients who will benefit the most from these procedures are those who would not wish to undergo surgery, those at prohibitively high risk for surgery, and those wishing to avoid ejaculatory dysfunction secondary to trans-urethral resection of the prostate (TURP) or open resection. Mechanical devices such as Temporary implantable nitinol device and Urolift appear to provide satisfying results with a favorable safety profile. Persistence of improvement is still questionable since follow-up longer than 5 years is not available for these methods. Of note, these methods may be of limited performance for larger prostates, in special, Urolift for those with a large median lobe or a prostate larger than 100 grams. Similarly, novel techniques for tissue ablation, including convective water vapor energy, appear to offer promising and safe results, yet with limited follow-up. Prostate artery embolization (PAE) is another safe procedure and an option for patients who are not suited for surgery, with satisfying short and medium-term follow-up but unknown results at long-term.

show abstract

Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience

Cited by 66 publications

References 11 publications

Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm

Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm

Rezum water vapour therapy for benign prostatic hyperplasia

Minimally invasive techniques for the treatment of benign prostatic hyperplasia

Contact Info

Product

Resources

About